S. Louis Bridges
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
S. Louis Bridges has a total of 672 co-authors. Here are the top co-authors by number of shared publications:
Laura B. Hughes
Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham Medicine, Birmingham, Alabama, USA
14 shared publications- Larry W. Moreland
University of Pittsburgh Pittsburgh Pennsylvania
13 shared publications - Leigh F. Callahan
Division of Rheumatology, Allergy and Immunology, Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA
8 shared publications Maria I. Danila
Affiliation University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States of America
7 shared publicationsBeth L. Jonas
University of North Carolina at Chapel Hill School of Medicine
6 shared publications- Robert P. Kimberly
University of Alabama at Birmingham
6 shared publications
Latest Publications
- 9 February 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (8) , 1636-1640
Big Data May Have Big Pitfalls: Ensuring Rigor in Rheumatic Disease Epidemiology
- 9 February 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (8) , 1636-1640
Big Data May Have Big Pitfalls: Ensuring Rigor in Rheumatic Disease Epidemiology
- 9 December 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (4) , 788-790
STOP ‐ing Rheumatoid Arthritis—Lessons Learned From the Latest Prevention Trial
- 9 December 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (4) , 788-790
STOP ‐ing Rheumatoid Arthritis—Lessons Learned From the Latest Prevention Trial
- 9 July 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (11) , 1465-1467
A Historical Perspective on Approaches to Understanding the Genetics of Systemic Lupus Erythematosus
- 9 July 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (11) , 1465-1467
A Historical Perspective on Approaches to Understanding the Genetics of Systemic Lupus Erythematosus
- Top Cited PapersOpen Access
- 17 March 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (6)
Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease currently with no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in at-risk populations prior to clinical onset is crucial to establishing effective prevention strategies. Here, we applied multimodal single-cell technologies (mass cytometry and CITE-Seq) to characterize the immunophenotypes in blood from at-risk individuals (ARIs) identified through the presence of serum antibodies against citrullinated protein antigens (ACPAs) and/or first-degree relative (FDR) status, as compared with patients with established RA and people in a healthy control group. We identified significant cell expansions in ARIs compared with controls, including CCR2 + CD4 + T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5 + CD8 + T cells. We also found that CD15 + classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5 lo naive B cell population was expanded in ACPA-positive FDRs. Further, we uncovered the molecular phenotype of the CCR2 + CD4 + T cells, expressing high levels of Th17- and Th22-related signature transcripts including CCR6 , IL23R , KLRB1 , CD96 , and IL22 . Our integrated study provides a promising approach to identify targets to improve prevention strategy development for RA.
- 17 March 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (6)
Top Cited PapersOpen AccessDeep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease currently with no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in at-risk populations prior to clinical onset is crucial to establishing effective prevention strategies. Here, we applied multimodal single-cell technologies (mass cytometry and CITE-Seq) to characterize the immunophenotypes in blood from at-risk individuals (ARIs) identified through the presence of serum antibodies against citrullinated protein antigens (ACPAs) and/or first-degree relative (FDR) status, as compared with patients with established RA and people in a healthy control group. We identified significant cell expansions in ARIs compared with controls, including CCR2 + CD4 + T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5 + CD8 + T cells. We also found that CD15 + classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5 lo naive B cell population was expanded in ACPA-positive FDRs. Further, we uncovered the molecular phenotype of the CCR2 + CD4 + T cells, expressing high levels of Th17- and Th22-related signature transcripts including CCR6 , IL23R , KLRB1 , CD96 , and IL22 . Our integrated study provides a promising approach to identify targets to improve prevention strategy development for RA.
- 17 November 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (5) , 497-498
J. Claude Bennett, MD, 1933–2024
- 17 November 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (5) , 497-498
J. Claude Bennett, MD, 1933–2024
- 1 August 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 76 (11) , 1577-1581
Curating Genetic Associations With Rheumatologic Autoimmune Diseases to Improve Patient Outcomes
- 1 August 2024
- Published by Wiley in Arthritis & Rheumatology
- Vol. 76 (11) , 1577-1581
Curating Genetic Associations With Rheumatologic Autoimmune Diseases to Improve Patient Outcomes
- 29 October 2023
- Published by Elsevier in Rheumatic Disease Clinics of North America
- Vol. 50 (1) , 57-63
J. Claude Bennett, MD
- 29 October 2023
- Published by Elsevier in Rheumatic Disease Clinics of North America
- Vol. 50 (1) , 57-63
J. Claude Bennett, MD
- Open Access
Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease with currently no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in ‘At-Risk’ populations prior to clinical disease onset is crucial to establishing effective prevention strategies. Here, we applied mass cytometry to deeply characterize the immunophenotypes in blood from At-Risk individuals identified through the presence of serum antibodies to citrullinated protein antigens (ACPA) and/or first-degree relative (FDR) status (n=52), as compared to established RA (n=67), and healthy controls (n=48). We identified significant cell expansions in At-Risk individuals compared with controls, including CCR2+CD4+ T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5+CD8+ T cells. We also found that CD15+ classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5 low naïve B cell population was expanded in ACPA-positive FDRs. Further, we developed an “RA immunophenotype score” classification method based on the degree of enrichment of cell states relevant to established RA patients. This score significantly distinguished At-Risk individuals from controls. In all, we systematically identified activated lymphocyte phenotypes in At-Risk individuals, along with immunophenotypic differences among both ACPA+ and ACPA-FDR At-Risk subpopulations. Our classification model provides a promising approach for understanding RA pathogenesis with the goal to further improve prevention strategies and identify novel therapeutic targets.
Open AccessDeep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease with currently no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in ‘At-Risk’ populations prior to clinical disease onset is crucial to establishing effective prevention strategies. Here, we applied mass cytometry to deeply characterize the immunophenotypes in blood from At-Risk individuals identified through the presence of serum antibodies to citrullinated protein antigens (ACPA) and/or first-degree relative (FDR) status (n=52), as compared to established RA (n=67), and healthy controls (n=48). We identified significant cell expansions in At-Risk individuals compared with controls, including CCR2+CD4+ T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5+CD8+ T cells. We also found that CD15+ classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5 low naïve B cell population was expanded in ACPA-positive FDRs. Further, we developed an “RA immunophenotype score” classification method based on the degree of enrichment of cell states relevant to established RA patients. This score significantly distinguished At-Risk individuals from controls. In all, we systematically identified activated lymphocyte phenotypes in At-Risk individuals, along with immunophenotypic differences among both ACPA+ and ACPA-FDR At-Risk subpopulations. Our classification model provides a promising approach for understanding RA pathogenesis with the goal to further improve prevention strategies and identify novel therapeutic targets.
- 4 April 2023
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 41 (6) , 1033-1039
Hypertension severity, apparent treatment resistant hypertension and hyperuricemia in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study
Background: Prior studies have identified an association between hypertension and hyperuricemia; however, there has been limited research on the association between hypertension severity and hyperuricemia. Method: We studied 997 Black and white adults with serum urate data from the reasons for geographic and racial differences in stroke (REGARDS) study. Hypertension was defined as SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or self-reported use of antihypertensive medication. Apparent treatment-resistant hypertension (aTRH) was defined as a SBP ≥ 140 mmHg or DBP ≥ 90 mmHg with concurrent use of three classes of antihypertensive medications, or taking four or more classes of antihypertensive medication regardless of BP level. Controlled BP was defined as SBP 6.0 mg/dl for women. After full multivariable adjustment, the odds ratio (OR) for hyperuricemia associated with hypertension was 1.60 [95% confidence interval (95% CI): 1.06–2.40]. Compared to participants not taking antihypertensive medication, the ORs for hyperuricemia for participants taking one, two and three classes of antihypertensive medication without aTRH were 1.98 (95% CI: 1.23–3.20), 2.08 (95% CI: 1.25–3.43), 4.31 (95% CI: 2.07–8.97), respectively, and 3.96 (95% CI: 1.75–8.96) for aTRH. Compared to participants without hypertension, the odds ratios for hyperuricemia were 1.67 (95% CI: 1.08–2.58) and 1.46 (95% CI: 0.88–2.44) among those with hypertension with and without controlled BP, respectively. Diuretic use was associated with a higher odds of hyperuricemia. Conclusion: This study suggests that individuals taking more classes of antihypertensive medication may benefit from monitoring for hyperuricemia.
- 4 April 2023
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 41 (6) , 1033-1039
Hypertension severity, apparent treatment resistant hypertension and hyperuricemia in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study
Background: Prior studies have identified an association between hypertension and hyperuricemia; however, there has been limited research on the association between hypertension severity and hyperuricemia. Method: We studied 997 Black and white adults with serum urate data from the reasons for geographic and racial differences in stroke (REGARDS) study. Hypertension was defined as SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or self-reported use of antihypertensive medication. Apparent treatment-resistant hypertension (aTRH) was defined as a SBP ≥ 140 mmHg or DBP ≥ 90 mmHg with concurrent use of three classes of antihypertensive medications, or taking four or more classes of antihypertensive medication regardless of BP level. Controlled BP was defined as SBP 6.0 mg/dl for women. After full multivariable adjustment, the odds ratio (OR) for hyperuricemia associated with hypertension was 1.60 [95% confidence interval (95% CI): 1.06–2.40]. Compared to participants not taking antihypertensive medication, the ORs for hyperuricemia for participants taking one, two and three classes of antihypertensive medication without aTRH were 1.98 (95% CI: 1.23–3.20), 2.08 (95% CI: 1.25–3.43), 4.31 (95% CI: 2.07–8.97), respectively, and 3.96 (95% CI: 1.75–8.96) for aTRH. Compared to participants without hypertension, the odds ratios for hyperuricemia were 1.67 (95% CI: 1.08–2.58) and 1.46 (95% CI: 0.88–2.44) among those with hypertension with and without controlled BP, respectively. Diuretic use was associated with a higher odds of hyperuricemia. Conclusion: This study suggests that individuals taking more classes of antihypertensive medication may benefit from monitoring for hyperuricemia.